This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a single-centre pharmacokinetic study with a crossover design. The 12 patients first received a continuous infusion of piperacillin-tazobactam and a single high dose of gentamicin. Then, after a washout period, they received an intermittent infusion of piperacillin-tazobactam and a single high dose of gentamicin. The authors did not report any procedures to mask the participants or investigators to the treatment method during administration of the therapy, or the assessment and analysis of the outcome.
The duration of follow-up was the length of the infusion. All 12 patients completed the continuous infusion part of the study. One patient withdrew from the intermittent infusion part of the study for reasons unrelated to the study, which were not reported.
Analysis of effectiveness
The basis of the analysis, in terms of intention to treat or treatment completers only, was not reported.
The primary outcomes were pharmacokinetic parameters for piperacillin before and after the administration of gentamicin. These were: the steady state concentration of piperacillin administered by continuous infusion; the maximum concentration of piperacillin administered by intermittent infusion; the elimination half-life of piperacillin administered by intermittent infusion; the area under the concentration-time curve for piperacillin administered by intermittent infusion.
Effectiveness results
For the continuous infusion of piperacillin, the mean steady state concentration of piperacillin was 28 (standard deviation, SD=6.9) microg/mL before the administration of gentamicin, and 29.7 (SD=7.0) microg/mL for the 9 hours following the absolute peak gentamicin concentration, (p=0.30).
The mean maximum concentration of piperacillin administered by intermittent infusion was 232 (SD=54) microg/mL before the introduction of gentamicin, and 253 (SD=83) microg/mL after, (p=0.67).
The mean elimination half-life of piperacillin administered by intermittent infusion was 0.81 (SD=0.22) hours before the introduction of gentamicin, and 0.89 (SD=0.23) hours after, (p=0.32).
The mean area under the concentration-time curve for piperacillin administered by intermittent infusion was 354 (SD=132) microg hours/mL before the introduction of gentamicin, and 315 (SD=73) microg hours/mL after (p=0.39).
Clinical conclusions
The authors concluded that administering once-daily gentamicin to healthy volunteers, who were receiving piperacillintazobactam as either a continuous or intermittent infusion, did not alter the pharmacokinetic parameters of either piperacillin or gentamicin. There was no clinically or statistically significant interaction.
Measure of benefits used in the economic analysis
The outcomes were reported in a disaggregated way and, as such, this was a cost-consequences analysis.
Direct costs
The resource quantities and the costs were not reported separately. The resource use and cost data were obtained from a time and motion study published in 1997, and from data for 296 patients treated in the 1997 to 1998 fiscal year. The direct costs to the hospital were included in the analysis. The costs of the acquisition, preparation and administration of
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Statistical analysis of costs
A statistical analysis of the costs was not reported.
Indirect Costs
The indirect costs were not included in the analysis as they were not appropriate to the perspective of the study.
Currency

US dollars ($)
. No currency conversion rates were reported.
Sensitivity analysis
One-way sensitivity analyses were conducted on the dose regimen and the unit costs of the intermittent infusion of piperacillin.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
Using hospital-based costs, the total costs for 296 patients given an infusion of piperacillin were:
$144,814 for a 4-hourly intermittent infusion of piperacillin 3.375 g; $96,542 for a 6-hourly intermittent infusion of piperacillin 3.375 g; $90,414 for an 8-hourly intermittent infusion of piperacillin 4.5 g; and $78,806 for a continuous infusion of piperacillin (500 mg/hour) plus a 4.5 g loading dose.
Using hospital-based cost data, the net savings associated with constant infusion were:
$66,008 versus a 4-hourly intermittent infusion of piperacillin 3.375 g; $17,736 versus a 6-hourly intermittent infusion of piperacillin 3.375 g; and $11,608 versus an 8-hourly intermittent infusion of piperacillin 4.5 g.
The costs did not include the costs of therapeutic failure, adverse events or side-effects. The authors reported that no adverse events were observed during the conduct of the study.
Synthesis of costs and benefits
The costs and the benefits were not combined in this cost-consequences study.
The sensitivity analysis gave the following results.
Using average wholesale price data, the costs were:
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